Your bank, your health insurer and even your favorite stores have also had their customers' data stolen by hackers.
Stocks in the health care sector are vulnerable to declines following the 2016 presidential election, according to S&P analyst Scott Kessler.
This drug stock has stumbled on a failed clinical trial, but here's why the stock is a bargain right now.
Namibia's human and natural resources offer limitless potential as a commercial hub and channel to the Southern African region that represents a market upwards of 300 million people
Seeking robust income in a world of low interest rates? Look no further than these two terrific REITs.
An Alzheimer's drug under development by Danish pharma Lundbeck failed a pivotal phase III study and Axovant suffered collateral damage.
UnitedHealth becomes the second major healthcare provider to scratch the insulin product from its 2017 medicines roster.
A member of the Royal Family of Serbia sees first hand how the refugee crisis is impacting children asks for help.
Mylan's MYL CEO Heather Bresch appeared in the House of Representatives to testify on the rising prices of EpiPens.
The Irish drugmaker isn't likely done making deals, even though it just made two, and it could take a look at Alder Biopharmaceuticals next, analysts believe.
Brace for extreme turbulence as Mylan's chief executive testifies before Congress and faces further public condemnation.
The pharmacy company presents a solid buying opportunity for investors who willing to hold for the long term.
When an experimental glaucoma drug is only marginally effective, one way to produce positive clinical trial results is to enroll patients with borderline glaucoma.
CEO Werner Baumann increases sales and margin forecasts for pharmaceuticals and insists Monsanto deal will deliver growth and improved profit.
The company could divest non-core assets after Starboard Value revealed a 4.6% stake.